Performance of careHPV for detecting high-grade cervical intraepithelial neoplasia among women living with HIV-1 in Burkina Faso and South Africa: HARP study

Background:The careHPV assay is a test for high-risk (HR) human papillomaviruses (HPV) detection designed to be affordable in resource-poor settings. We evaluated the performance of careHPV screening among 1052 women living with HIV/AIDS included in the HARP (HPV in Africa Research Partnership) study in Burkina Faso (BF) and South Africa (SA).Methods:Cervical samples were tested for HR-HPV by the careHPV and the INNO-LiPA HPV genotyping Extra assays. All women had Pap smear testing, visual inspection with acetic acid/Lugol’s iodine (VIA/VILI) and colposcopy. Cervical biopsies were obtained for participants who were HR-HPV DNA positive by careHPV or who had abnormalities detected on cytology, VIA/VILI or colposcopy.Results:Overall, 45.1% of women had a positive careHPV test (46.5% in BF, 43.8% in SA). The careHPV positivity rate increased with the grade of cytological lesions. Sensitivity and specificity of careHPV for the diagnosis of CIN2+ (n=60, both countries combined) were 93.3% (95% confidence interval (CI): 83.8–98.2) and 57.9% (95% CI: 54.5–61.2), respectively. Specificity increased with CD4 count. careHPV had a similar clinical sensitivity but higher specificity than the INNO-LiPA assay for detection of CIN2+.Conclusions:Our results suggest that careHPV testing is a reliable tool for cervical cancer screening in HIV-1-infected women in sub-Saharan Africa.

[1]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[2]  J. Fregnani,et al.  Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test. , 2013, Gynecologic oncology.

[3]  P. Bansil,et al.  Performance of Cervical Cancer Screening Techniques in HIV-Infected Women in Uganda , 2015, Journal of lower genital tract disease.

[4]  S. Wacholder,et al.  Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria , 2012, International journal of cancer.

[5]  M. Hudgens,et al.  Validation of Cervical Cancer Screening Methods in HIV Positive Women from Johannesburg South Africa , 2013, PloS one.

[6]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[7]  Joakim Dillner,et al.  Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. , 2008, Vaccine.

[8]  Mardge H. Cohen,et al.  Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. , 2009, The Journal of infectious diseases.

[9]  J. Smith.  Bethesda 2001 , 2002, Cytopathology : official journal of the British Society for Clinical Cytology.

[10]  S. Franceschi,et al.  Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya , 2012, British Journal of Cancer.

[11]  Y. Qiao,et al.  A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China. , 2014, Journal of virological methods.

[12]  Jennifer S. Smith,et al.  HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[13]  L. Denny,et al.  Cervical Cancer in Africa , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[14]  M. B. Diouf,et al.  Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. , 2003, Journal of Infectious Diseases.

[15]  S. Delany-Moretlwe,et al.  Comparison of Analytical and Clinical Performances of the Digene HC2 HPV DNA Assay and the INNO-LiPA HPV Genotyping Assay for Detecting High-Risk HPV Infection and Cervical Neoplasia Among HIV-Positive African Women , 2015, Journal of acquired immune deficiency syndromes.

[16]  S. Delany-Moretlwe,et al.  Comparison of careHPV and Hybrid Capture 2 Assays for Detection of High-Risk Human Papillomavirus DNA in Cervical Samples from HIV-1-Infected African Women , 2013, Journal of Clinical Microbiology.

[17]  H. Weiss,et al.  Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso , 2006, British Journal of Cancer.

[18]  P. Michelow,et al.  Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa , 2009, Cancer Causes & Control.

[19]  Feng Chen,et al.  A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. , 2008, The Lancet. Oncology.

[20]  S. Bhambhani,et al.  CareHPV cervical cancer screening demonstration in a rural population of north India. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[21]  Y. Qiao,et al.  The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.